EURONEXT-AMS$PHAR
Pharming Group NV · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Pharming Q3 2025: $97.3M revenue (+30%) as RUCONEST and Joenja drive profitability
Pharming Group reported third quarter 2025 total revenues of $97.3 million, up 30% from $74.8 million in Q3 2024, driven by 29% growth in RUCONEST to $82.2 million and 35% growth in Joenja (leniolisib) to $15.1 million. Operating profit surged 285% to $15.8 million from $4.1 million, and net income was $7.5 million ($0.011 basic EPS) versus a $1.1 million net loss a year ago. Nine-month revenues reached $269.6 million (+32%) with operating profit of $19.6 million. The company generated $32.0 million in operating cash flow during the quarter and ended with $168.9 million in cash and equivalents. Management raised full-year 2025 revenue guidance to $365–375 million from $335–350 million. FDA granted priority review of the leniolisib sNDA for pediatric APDS patients aged 4–11 with a PDUFA date of January 31, 2026.
- Q3 total revenue grew 30% to $97.3M; RUCONEST was $82.2M (+29%) and Joenja was $15.1M (+35%).
- Q3 operating profit rose 285% to $15.8M; net income was $7.5M ($0.011 basic EPS).
- Nine-month revenue was $269.6M (+32%) with $44.0M of operating cash flow.
- 2025 revenue guidance raised to $365–375M from $335–350M.
- FDA priority review granted for leniolisib pediatric label expansion with PDUFA date January 31, 2026.
Headline financials
Revenue & EPS history
Pharming Group NV · Revenue · Quarterly
$97.3M
Revenue by segment
Pharming Group NV · $97.3M total across 2 segments · Q3 2025
- RUCONEST$82.2M—84.5%
- Joenja (leniolisib)$15.1M—15.5%
Forward guidance
Pharming raised 2025 total revenue guidance to $365–375 million (23–26% growth) and expects operating expenses of $304–308 million excluding one-time restructuring costs of approximately $7 million in Q4.
Tailwinds
- RUCONEST continued US patient and prescriber growth despite new oral HAE competition.
- Joenja revenue grew 35% with 116 US patients on paid therapy and UK launch contributing.
Headwinds
- Company withdrawing RUCONEST from non-US markets where sales were only 1.3% of revenue.
- G&A restructuring includes 20% net headcount reduction with ~$7M one-time Q4 costs.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q3 2025
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-1.0%
Avg return
30 days after
38%
6 / 16 earnings
Positive
+12.5%
Q2 2022
Best reaction
-26.8%
Q4 2026
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -26.8% | -93.2% | -93.1% | |
| Q3 2025 | +11.5% | +19.8% | +27.1% | |
| Q2 2024 | -8.4% | -2.9% | -7.7% | |
| Q1 2024 | -1.7% | -3.3% | -12.6% | |
| Q4 2023 | -1.7% | -1.0% | -5.2% | |
| Q3 2023 | +5.0% | +14.0% | +12.0% | |
| Q2 2023 | +4.2% | -0.5% | -1.4% | |
| Q1 2023 | -20.4% | -7.7% | -4.8% | |
| Q4 2022 | -1.6% | -14.2% | -6.2% | |
| Q3 2022 | +0.0% | +24.3% | +28.2% | |
| Q2 2022 | +12.5% | +29.6% | +59.2% | |
| Q1 2022 | +3.8% | +7.7% | +7.9% | |
| Q4 2021 | +1.3% | -2.7% | +5.8% | |
| Q3 2021 | -12.6% | -7.5% | -13.6% | |
| Q2 2021 | -6.8% | -8.8% | -4.0% | |
| Q1 2021 | -8.4% | -6.9% | -7.0% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro